Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;35(8):516-527.
doi: 10.1016/j.urolonc.2017.06.043.

Current clinical trials in non-muscle invasive bladder cancer

Mohammad Rashid Siddiqui  1 , Campbell Grant  2 , Thomas Sanford  1 , Piyush K Agarwal  3
Affiliations
Review

Current clinical trials in non-muscle invasive bladder cancer

Mohammad Rashid Siddiqui et al. Urol Oncol. 2017 Aug.

Abstract

Background: The treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC.

Method: We reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014.

Result: Many trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failure patients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested.

Conclusion: This comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC.

Keywords: BCG failure; BCG naive; BCG recurrent; BCG refractory; BCG unresponsive; Non–muscle invasive bladder cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A) The total number of clinical trials in NMIBC reviewed in this article. B) Summary of recently completed or on-going clinical trials in BCG-Naïve patients. C) Summary of recently completed or on-going clinical trials in BCG-Unresponsive patients. D) Summary of recently completed or on-going clinical trials in patients with either BCG-Naïve or BCG-unresponsive NMIBC.
See this image and copyright information in PMC

References

    1. Kaufman DS, Shipley WU, Feldman AS, Jemal A, Siegal R, Ward E, et al. Bladder cancer. Lancet (London, England) 2009;374:239–49. doi: 10.1016/S0140-6736(09)60491-8. - DOI - PubMed
    1. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–30. - PubMed
    1. Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin. Cancer. 2017;123:390–400. doi: 10.1002/cncr.30392. - DOI - PubMed
    1. Important Updates Regarding Sanofi Pasteur’s BCG Announcement. Am Urol Assoc. 2016 http://www.auanet.org/press-media/2016-BGC-announcement.cfm.
    1. Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep. 2016;17:68. doi: 10.1007/s11934-016-0625-z. - DOI - PMC - PubMed

Publication types

MeSH terms